Age-related bone diseases, such as osteoporosis, osteoarthritis, and bone fragility, are major causes of morbidity and reduced quality of life in the elderly, where there are significant unmet clinical needs. Current therapies ignore the crucial vascular environment and lack safe, long-term anabolic options, leaving millions vulnerable to fragile bones, impaired healing, and low quality of life. Nimverta is developing a first-in-class peptide therapy that regenerates both bone and its supporting vasculature by leveraging natural physiological pathways, unlocking the potential for safe, long-term treatment.